# Maryland Prescription Drug Affordability Board

PDAB Program Overview

-----

Oregon Senate Committee on Health Care

Presentation by: Andrew York, Executive Director

03/22/2021



## Prescription Drug Affordability Board

- The Maryland Prescription Drug Affordability Board (PDAB) was created to study the prescription drug market in Maryland, and protect the State and its residents from the high costs of prescription drug products
- Throughout this year, the Board will analyze Maryland's pharmaceutical distribution and payment system, review possible policy options to lower the cost of prescription drugs, and report its findings to the General Assembly
- Possible options include, but are not limited to, setting upper payment limits, a reverse auction marketplace, and implementing a bulk purchasing process



#### History and Milestones

- Maryland passed legislation creating the Prescription Drug Affordability Board in 2019
- Board members appointed in 2019 and 2021
- Funding secured in 2021
  - Legislation allows PDAB to develop regulations to assess annual fees on manufacturers, pharmacy benefit managers, carriers, and wholesale distributors that sell prescription drugs in the state



#### Current Work

- Drafting two reports due December 2021
  - Study of the pharmaceutical distribution and payment system, including possible policy options and Board recommendations
    - Includes upper payment limits (UPLs), reverse auctions, and bulk purchasing
  - Report on price trends pf prescription products, and the number of drugs that were subject to Board review
- Board must decide if they want to move forward with UPLs for state and local government
  - If so, Board must develop a plan of action for setting UPLs and submit the plan of action to the Legislative Policy Committee of the Maryland General Assembly



### Questions and Feedback

Please visit pdab.maryland.gov for updates on the PDAB and its progress on studying Maryland's pharmaceutical market.

Please also feel free to contact the PDAB with any questions or concerns at: andrew.york@maryland.gov

